Lancet Diabetes & Endocrinology

Article	Citations
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	963
World Health Assembly ratifies first global diabetes targets	890
A framework for improving diabetes care in humanitarian emergencies	599
Mark Atkinson: bringing two worlds together	527
Vitamin D to prevent acute respiratory infections	519
What's preventing us from curbing the obesity crisis?	419
Direct-to-consumer services: improving access to care for people with diabetes and obesity	405
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	383
Better testing and labelling of drugs for people with obesity	372
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	367
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	356
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	339
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	324
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	322
South Africa to produce insulin for Africa in 2024	298
Anand Hardikar: a scientific nomad searching for the truth	277
Implications of technology guidelines for low-income and middle-income countries	248
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK	245
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	242
A compass for navigating the perils of hypertriglyceridaemia	195
Obesity in people living with type 1 diabetes	194
Nutritional intake and bone health	193
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	193
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	185
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	185

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	180
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	179
Jennifer Manne-Goehler: at the crossroads of pandemics	168
The uncomfortable truth about kidney disease in type 1 diabetes	161
The role of nurses in diabetes care: challenges and opportunities	159
The promise and hope of GLP-1 receptor agonists	154
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial	153
What does renal failure teach us about our National Health System?	151
A roadmap for integrating mental health and diabetes services	131
Challenging diabetes stigma starts and ends with all of us	128
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	127
Dapagliflozin in patients with COVID-19: truth or dare	124
Putting wellbeing at the core of diabetes care	123
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	123
Rising diabetes diagnosis in long COVID	120
Glycaemic index as part of the diabetes prevention strategy	118
Principles for virtual health care to deliver real equity in diabetes	117
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	113
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	113
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	111
The changing character of diabetes complications	108
Lebanon: insulin out of reach after subsidies lifted	107
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss	104
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	103
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	99
Childhood obesity: a growing pandemic	97
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	96
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	94
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	92
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	91
Hypothalamic obesity: from basic mechanisms to clinical perspectives	91
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	90
Improving HbA1c levels with advanced hybrid closed-loop therapy	89
Women in diabetes research: stepping towards equity	88
Is it time to re-assess the development of thyroid function reference ranges?	85
Blood pressure control according to type 2 diabetes status	84
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	83
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	82
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	82
Glucagon, from past to present: a century of intensive research and controversies	82
Male hypogonadism: pathogenesis, diagnosis, and management	81
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	80
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	77
Diabetes: knowing your risk matters	76
Gender equality: timely and timeless	76
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	74
Homing in on the causes of male infertility	73
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	70
CONCEPTT to care: the science of implementation in diabetes care	66
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	63

Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	63
On the occasion of International Women's Day	62
Improving support for university students with type 1 diabetes	62
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes	62
Vanita Aroda: the accidental role model… by no accident	60
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	59
Health disparities in transgender people	59
Central diabetes insipidus from a patient's perspective	59
Chronicling insulin from discovery to crisis	58
Food policies: in times of COVID-19 and beyond	57
Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28	57
Embracing community sport to promote global health	56
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	54
Teplizumab approval for type 1 diabetes in the USA	53
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	53
European Commission classifies obesity as a chronic disease	52
Screening type 1 diabetes and celiac disease by law	51
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	51
Vitamin D and fractures	50
Technology for type 1 diabetes: what impact will it have?	49
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	49
Methodological considerations in D-health cancer mortality results – Authors' reply	49
Management of menopause: a view towards prevention	49
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	49
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction	48
How do clinicians integrate oral octreotide into their treatment plan for acromegaly?	47
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia	47
Young adult-onset type 2 diabetes heralds a poor prognosis	45
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	45
Insulin regimens during type 1 diabetes pregnancy	44
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	44
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	44
Exposure to endocrine-disrupting chemicals in utero and thyroid cancer risk in offspring – Authors' reply	43
Blood glucose targets in the critically ill: is one size fits all still appropriate?	43
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	42
Automated insulin delivery postpartum: insights from the AiDAPT study extension	42
RETRACTED: Targeting of vitamin D supplementation to individuals with deficiency	41
Is the impact of add on heart failure therapy influenced by background therapy?	41
An inclusive approach to people with disabilities in diabetes care and education	41
First, do no harm	41
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	41
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	41
Viswanathan Mohan: a dynasty of diabetology	41
Health policy and public health implications of obesity in China	41
Enhancing global access to diabetes medicines: policy lessons from the HIV response	39
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	39
Creating diabetes guidelines for the individual not just the illness	39
MarÍa José Redondo: rethinking type 1 diabetes	39
Impact of higher BMI on cardiometabolic risk: does height matter?	38
Primum non nocere—first, do no harm with bariatric surgery	38
Exposure to endocrine-disrupting chemicals in utero and thyroid cancer risk in offspring	38
ORION-3: delivering lipid lowering treatment for longer	38
How clinically relevant is statin-induced diabetes?	38
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	38
Disparities in fragility fracture and osteoporosis care in Africa	37
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	36
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	36
Redefining obesity: advancing care for better lives	36
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	36
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	36
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	36
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	36
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	35
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	35
The WHO Global Diabetes Compact: a new initiative to support people living with diabetes	34
Risks and burdens of incident diabetes in long COVID: a cohort study	34
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials	34
Addressing health and demographic challenges in Japan's ageing society	33
Gender disparities in publishing: from words to actions	33
What's in a decade?	33
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial	33
Mendelian randomisation and vitamin D: the importance of model assumptions	32
Data processing in the DMagic cluster randomised controlled trial	32
The growing global burden of thyroid cancer overdiagnosis	31
Setmelanotide: new promise for the treatment of hypothalamic obesity?	31
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era	31
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	30
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	29
Disease modifying therapies in diabetes and endocrinology	29
Diabetes and the WHO Model List of Essential Medicines	29

The potential role for artificial intelligence in fracture risk prediction	28
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	28
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	28
Sleep: a neglected public health issue	28
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	27
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	27
Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care	26
Osteoporosis in men	26
The double burden of poor diets	26
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	26
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	26
Iodine deficiency in Europe: vigilance and action required	26
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	25
Sex differences in familial hypercholesterolaemia	25
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	24
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	24
Revisiting osteoporosis guidelines	24
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	23
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study	23
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	23
Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records	23
The power of resilience	22
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	22
Endocrine health in survivors of adult-onset cancer	22
PFAS: here today—here tomorrow	22
A global plastics treaty to protect endocrine health	21
Bariatric surgery in children with obesity and type 2 diabetes	21
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	21
From research to policy: still a long way to go	21
Cognitive decline in longstanding type 1 diabetes: a role for severe hypoglycaemia	21
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	21
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	21
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	20
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	20
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	20
Sexual dimorphism in COVID-19: potential clinical and public health implications	20
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	20
Statins for Graves' orbitopathy: a new tool for prevention and treatment?	20
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	20
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	20
The voices of lived experience in diabetes and endocrinology	19
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	19
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial	19
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium	19
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	19
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	19
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality – Authors' reply	19
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	18
Predicting and preventing heart failure in type 2 diabetes	18
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies	18
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	17
Does tirzepatide treatment improve skeletal muscle composition?	17
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	17
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	17
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	17
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	16
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention	16
COVID-19 targets human adrenal glands	16
Type 1 diabetes: one size does not fit all	15
The ISPAD Clinical Practice Consensus Guidelines 2022: how far we have come and the distance still to go	15
Diabetes educators: rewriting the narrative	15
Obesity in Qatar: current and future strategies	15
Denosumab in the treatment of osteoporosis associated with chronic kidney disease	14
Migrant health: a global responsibility	14
Correction to Lancet Diabetes Endocrinol 2023; 11: 567–77	14
Is autonomous cortisol secretion sexually dimorphic?	14
The evidence for achondroplasia in 1st century AD Italy	14
Endpoints for clinical trials in type 1 diabetes drug development	14
Access to insulin and diabetes care in the Philippines	14
Food additive emulsifiers and risk of type 2 diabetes	14
The actual burden of obesity—accounting for multimorbidity	13
Vitamin D and acute respiratory infections: a definitive answer?	13
Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial	13
Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity	13
Heart failure: now centre-stage in diabetes	13
Causes, prevention, and management of diabetes-related foot ulcers	13
Alarming rise in young-onset type 2 diabetes	13
Clinical management and treatment of obesity in China	12
Osteoporosis in the USA: prevention and unmet needs	12
Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment	12
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada	12
Polycystic ovary syndrome	12
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, paralle	12
Why does visceral adiposity not explain higher type 2 diabetes prevalence in Asian Indians?	12
Answering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries	11
On the road to universal screening for risk of type 1 diabetes	11
Diabetes education: the key to a brighter tomorrow	11
Prequalification of insulin: what is missing?	11
The enduring effect of the COVID-19 pandemic on diabetes	11
Eating disorders: care not keeping up with demand	10
Closed-loop systems: a bridge to cell therapy for type 1 diabetes?	10
Melatonin: is it really a cardiovascular wonder pill for shift workers?	10
Bariatric tourism	10
Diabetes in humanitarian crises	10
Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia	10